Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

Targeted Oncology
Elvira SchmidtFlorence Marteau

Abstract

Cabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC). To indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aRCC. We conducted a systematic literature review (SLR) to identify randomized controlled studies in the first-line setting for aRCC. The outcomes analyzed were overall survival (OS) and progression-free survival (PFS). A network meta-analysis (NMA) was conducted comparing OS and PFS hazard ratios (HRs). Thirteen studies were identified in the SLR to be eligible for inclusion in the NMA. The overall study populations were heterogeneous in terms of risk groups; some studies included favorable risk patients. In intermediate-risk patients, HRs (95% confidence interval) for PFS were 0.52 (0.33, 0.82), 0.46 (0.26, 0.80), 0.20 (0.12, 0.36), and 0.37 (0.20, 0.68) when cabozantinib was compared with sunitinib, sorafenib, interferon (IFN), or bevacizumab plus IFN, respectively. In poor-risk patients, the NMA also demonstrated significant superiority in terms of PFS for cabozantinib; HRs were 0.31 (0.11, 0.90), 0.22 (0.06, 0.87), 0.16 (0.04, 0.64), and 0.20 (0.05, 0.88), when cabozantinib was compared with sunitini...Continue Reading

References

Nov 1, 1988·Computer Methods and Programs in Biomedicine·N Campos-Filho, E L Franco
Oct 27, 1999·The Journal of Thoracic and Cardiovascular Surgery·D W Wormuth
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Oct 15, 2005·BMJ : British Medical Journal·Deborah M CaldwellJ P T Higgins
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Mar 4, 2008·Cancer Treatment Reviews·Kiran GuptaClaudie Charbonneau
Oct 7, 2008·The Cancer Journal·Wong-Ho Chow, Susan S Devesa
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Nov 10, 2011·International Journal of Clinical Oncology·Shiro HinotsuHideyuki Akaza
Jan 17, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cora N SternbergIan D Davis
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerThomas E Hutson
Apr 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierDavid Cella
May 3, 2014·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Jan 27, 2015·European Urology·Borje LjungbergAxel Bex
Dec 1, 2012·Research Synthesis Methods·Gerta Rücker
Aug 1, 2015·BMC Medical Research Methodology·Gerta Rücker, Guido Schwarzer
Aug 4, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jose Manuel Ruiz-MoralesDaniel Y C Heng
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Committee
Nov 9, 2016·Critical Reviews in Oncology/hematology·Benoît RousseauChristophe Tournigand
May 19, 2017·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Aly-Khan A LalaniNaveen S Basappa
May 27, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriDaniel George
Aug 2, 2017·ESMO Open·Alejo Rodriguez-VidaMichiel H Strijbos
Nov 28, 2018·The Cochrane Database of Systematic Reviews·Nancy MedleyZarko Alfirevic

❮ Previous
Next ❯

Citations

May 28, 2020·Journal of Clinical Medicine·Antonella ArgentieroNicola Silvestris
Jan 27, 2019·Drugs & Therapy Perspectives : for Rational Drug Selection and Use·Katherine A Lyseng-Williamson
May 20, 2020·Advances in Therapy·Robin K KelleyGhassan K Abou-Alfa
Mar 4, 2021·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN CheckMate 9ER Investigators

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00117637
NCT00065468
NCT00083889

Software Mentioned

R
COMPARZ
netmeta
CABOSUN
TORAVA
PERCY Quattro

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.